Welcome to our dedicated page for Ventas SEC filings (Ticker: VTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ventas, Inc. filings document the regulatory record of a healthcare real estate investment trust whose common stock trades on the New York Stock Exchange under VTR. The company’s disclosures include Form 8-K reports for operating results, quarterly and annual earnings releases, dividend-related events, material financing agreements and capital markets activity.
Recent filings also cover amendments to credit facilities, registered senior notes issued by Ventas Realty, Limited Partnership and guaranteed by Ventas, ATM sales agreement updates, officer-transition disclosures and proxy materials addressing director elections, executive compensation, shareholder voting matters and governance.
Ventas, Inc. (VTR): Form 144 notice of proposed sale
Debra Cafaro filed to sell 19,250 shares of Ventas common stock, with an aggregate market value $1,449,348.10. The approximate sale date is November 5, 2025 on the NYSE, through Merrill Lynch. The shares were acquired the same day via a broker-assisted exercise of employee stock options. Ventas reported 469,732,824 shares outstanding.
Recent sales disclosed for the past three months include 317,258 shares on October 30, 2025 for $23,554,765.13 and 219,515 shares on October 20, 2025 for $15,656,406.48, among other smaller transactions.
Ventas, Inc. (VTR) filed a Form 144 indicating a proposed sale of 870 shares of common stock with an aggregate market value of $65,493.95. The filing lists Northern Trust Securities, Inc. as broker and an approximate sale date of 11/05/2025 on the NYSE. The shares were acquired as compensation on 02/01/2023.
Recent activity disclosed for the same seller includes sales of 406 shares for $28,418.94 on 09/15/2025, 2,040 shares for $142,779.60 on 09/30/2025, 2,554 shares for $179,435.36 on 10/01/2025, and 3,924 shares for $294,286.66 on 11/04/2025. Shares outstanding were 469,732,824 as of the filing’s reference line; this is a baseline figure, not the amount being offered.
Ventas, Inc. (VTR) reported a Form 144 notice indicating that insider Debra Cafaro plans to sell up to 11,452 shares of common stock through Merrill Lynch. The filing lists an aggregate market value of $859,147.56, with an approximate sale date of 11/04/2025 on the NYSE.
The shares to be sold were acquired via a broker-assisted exercise of employee stock options on 11/04/2025. The notice also lists recent sales in the past three months, including 317,258 shares sold on 10/30/2025 for $23,554,765.13 and 219,515 shares sold on 10/20/2025 for $15,656,406.48. Shares outstanding were 469,732,824.
Ventas, Inc. (VTR) filed a Form 144 notice for the proposed sale of 3,924 shares of common stock, shown with an aggregate market value of $294,286.66. The shares are listed for sale through Northern Trust Securities, Inc. on the NYSE, with an approximate sale date of 11/04/2025.
The securities were acquired as compensation shares on 02/01/2023. As context, 469,732,824 shares were outstanding. The past three months section lists sales attributed to Peter J. Bulgarelli: 406 shares for $28,418.94 on 09/15/2025, 2,040 shares for $142,779.60 on 09/30/2025, and 2,554 shares for $179,435.36 on 10/01/2025.
Ventas, Inc. (VTR) reported insider transactions by Chair and CEO Debra A. Cafaro. On 10/30/2025 and 11/03/2025, she exercised multiple fully vested stock options nearing expiration and sold the underlying shares, all pursuant to a Rule 10b5-1 trading plan entered on March 28, 2024.
Option exercises occurred at strike prices of $65.45, $73.71, $63.24, and $62.22. The corresponding share sales were executed at weighted average prices within disclosed ranges, including $74.00–$74.68 and $72.05–$74.71. Following these transactions, Cafaro beneficially owns 1,145,695 Ventas common shares directly and holds 113,548 unexercised options.
Ventas, Inc. (VTR) filed a Form 144 notice for a planned sale of 20,644 shares of common stock. The filing lists an aggregate market value of $1,524,690.62, an approximate sale date of 11/03/2025, execution on the NYSE, and Merrill Lynch as broker. Shares outstanding are stated as 469,732,824.
The securities to be sold were acquired on 11/03/2025 via exercise of employee stock options, with a broker-assisted exercise noted. Recent insider transactions disclosed in the filing include sales attributed to Debra Cafaro: 10,322 shares on 09/02/2025 for $699,863.18; 10,322 shares on 10/01/2025 for $724,985.92; 219,515 shares on 10/20/2025 for $15,656,406.48; and 317,258 shares on 10/30/2025 for $23,554,765.13.
Ventas, Inc. (VTR): Debra Cafaro filed a Form 144 notice to sell 317,258 shares of Ventas common stock, with an aggregate market value of $23,554,765.13. The filing lists Merrill Lynch as broker, an approximate sale date of 10/30/2025, and the NYSE as the exchange. Ventas had 454,471,192 shares outstanding.
The shares to be sold were acquired on 10/30/2025 through a broker-assisted exercise of employee stock options in the same amount of 317,258 shares. Recent activity disclosed includes sales by Debra Cafaro over the past three months: 10,322 shares on 08/01/2025 for $695,722.37, 10,322 on 09/02/2025 for $699,863.18, 10,322 on 10/01/2025 for $724,985.92, and 219,515 on 10/20/2025 for $15,656,406.48.
Ventas, Inc. (VTR) reported stronger Q3 2025 results. Revenue rose to $1.49 billion from $1.24 billion, driven by senior housing and outpatient assets. Net income attributable to common stockholders was $66.0 million, up from $19.2 million, with diluted EPS of $0.14 versus $0.05.
For the nine months, revenue reached $4.27 billion versus $3.64 billion, and net income attributable to common stockholders was $181.2 million versus $24.3 million. Operating cash flow was $1.18 billion. The company expanded its SHOP platform, acquiring 41 communities for $2.0 billion and later six more for $161.4 million, while disposing of assets for $168.8 million. Impairments totaled $85.4 million year‑to‑date.
Debt decreased to $12.57 billion from $13.52 billion as Ventas repaid $1.05 billion of 2025 notes and issued $500 million of 5.10% notes due 2032. Shares outstanding were 469,732,824 as of October 27, 2025. Segment NOI for the nine months was $1.77 billion, led by SHOP at $853.2 million.
Ventas, Inc. (VTR) furnished an 8-K announcing it issued a press release with results of operations for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference into Item 2.02.
The company states the information in Item 2.02, including Exhibit 99.1, is being furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act. Exhibits include 99.1 and the Inline XBRL cover page (104).
Ventas (VTR) disclosed a Form 4 for Debra A. Cafaro, its Chairman and CEO. On 10/20/2025, she exercised stock options for 185,283 shares at $62.22 and 34,232 shares at $65.45, then sold the underlying shares at a weighted average price of $71.3227 under a Rule 10b5-1 plan entered into on March 28, 2024. The sales occurred in multiple transactions between $71.00 and $71.50. After these transactions, she directly beneficially owned 1,145,695 shares and held 451,450 unexercised options.